Suppr超能文献

对抗非酒精性脂肪性肝病的潜在治疗靶点和有前景的药物

Potential Therapeutic Targets and Promising Agents for Combating NAFLD.

作者信息

Umemura Atsushi, Kataoka Seita, Okuda Keiichiro, Seko Yuya, Yamaguchi Kanji, Moriguchi Michihisa, Okanoue Takeshi, Itoh Yoshito

机构信息

Department of Pharmacology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kamigyo-ku, Kyoto 602-8566, Japan.

出版信息

Biomedicines. 2022 Apr 14;10(4):901. doi: 10.3390/biomedicines10040901.

Abstract

Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide because of the global increases in obesity, dyslipidemia, hypertension, and type 2 diabetes mellitus. Contrary to the advancements in therapies for viral hepatitis, effective treatments remain unestablished for patients with NAFLD. NAFLD, including NASH, is characterized by steatosis, inflammation, hepatic necrosis, and fibrosis. Despite our understanding of its pathophysiology, there are currently no effective treatments for NAFLD. In this review, we provide an update on the known pathophysiological mechanisms involved in the development of NAFLD and the role of hepatic stellate cells, and summarize the potential therapeutic agents, including natural products, for NAFLD.

摘要

非酒精性脂肪性肝病(NAFLD),包括非酒精性脂肪性肝炎(NASH),由于全球肥胖、血脂异常、高血压和2型糖尿病的发病率增加,正成为全球肝硬化和肝癌日益常见的病因。与病毒性肝炎治疗方面的进展相反,NAFLD患者仍未确立有效的治疗方法。NAFLD,包括NASH,其特征为脂肪变性、炎症、肝坏死和纤维化。尽管我们对其病理生理学有所了解,但目前尚无针对NAFLD的有效治疗方法。在本综述中,我们提供了有关NAFLD发生过程中已知病理生理机制以及肝星状细胞作用的最新信息,并总结了包括天然产物在内的NAFLD潜在治疗药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b714/9032837/c025bc2563ad/biomedicines-10-00901-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验